Health Care/Hospital News & Press Release Distribution

/DISREGARD RELEASE: Seegene Inc./

We are advised by Seegene Inc. that journalists and other readers should disregard the news release, Seegene reports solid results in the first quarter of 2021 withKRW 351.8 billion, issued 12-May-2021 over PR Newswire....

2021-05-21 09:36 16077

Johnson & Johnson Medical Korea Ltd. and Johnson & Johnson Innovation LLC Announce Launch of Seoul Innovation QuickFire Challenge on Smart Surgery in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute

- QuickFire Challenge calls on innovators to submit novel ideas with the potential to transform the surgical pathway for optimized care, cost savings, and improved patient outcomes. - Awardee(s) will receive grant funding from a total of up to KRW150,000,0001 , one year of residency at the Seoul ...

2021-05-21 05:00 3069

The pre-registration channel of 2021 Shanghai International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare (AID 2021) for visitors officially opens

SHANGHAI, May 20, 2021 /PRNewswire/ -- The 2021 Shanghai International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare, also known as AID 2021, will be heldJune 9th-11th 2021 in Halls W3-W5 of the Shanghai New International Expo Center. The pre-registration channel for visitors ...

2021-05-21 01:00 1280

BioVaxys Announces Appointment of Policy Advisor

VANCOUVER, BC, May 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:BVAXF)("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products, today announced the appointment ofAdam Coutts, PhD, as Policy ...

2021-05-20 20:00 11306

Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer

SHANGHAI, May 20, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products inGreater China and other parts of Asia, announced today that sacit...

2021-05-20 19:04 4507

Invitation to Elekta's Capital Markets Day 2021

STOCKHOLM, May 20, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) invites investors, analysts and financial media representatives to join Elekta's digital Capital Markets Day (CMD) onJune 7, 2021. Speakers at the event will include Gustaf Salford, President and CEO,Johan Adebäck, CFO, and several other ...

2021-05-20 17:03 8302

TricValve® Transcatheter Bicaval Valves System Receives CE Mark

HONG KONG, May 20, 2021 /PRNewswire/ -- OrbusNeich® Medical Company Ltd. and P&F Products & Features®, under the joint partnership OrbusNeich P&F, today announced that the TricValve® Transcatheter Bicaval Valves System has received CE mark approval. The TricValve® Transcatheter Bicaval Valve (bi...

2021-05-20 17:00 1526

European Wellness and Dongci Join Forces To Bring Regenerative Medicine To Shandong, China

KOTA KINABALU, Malaysia, May 20, 2021 /PRNewswire/ -- European Wellness Biomedical Group has signed a memorandum of understanding (MOU) with Yantai Dongci ZhenAn Hospital Group to develop an exclusive multimillion dollar-project Regenerative Medicine Center inShandong, China. In a digital signin...

2021-05-20 16:54 2393

The senior care industry in China enjoys a bright future: 18.7% of population aged 60 or above

SHANGHAI, May 20, 2021 /PRNewswire/ -- The 2021 Shanghai International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare, also known as AID 2021, will be heldJune 9th-11th 2021 in Halls W3-W5 of the Shanghai New International Expo Center. The pre-registration channel for visitors ...

2021-05-20 16:52 1516

Regent Pacific's Deep Longevity Announces Partnership with LifeHub & LifeClinic in Hong Kong

HONG KONG, May 20, 2021 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK)'s wholly owned Deep Longevity, Inc, a leading provider of deep biomarkers of aging and longevity is pleased to announce a c...

2021-05-20 12:00 8911

Idealmed GHS, part of European health group IGHS, commissions new Oman International Hospital in Muscat, Oman

MUSCAT, Oman, May 20, 2021 /PRNewswire/ -- The Idealmed Global Healthcare Services (Idealmed GHS), part of the european health group IGHS, based in Coimbra,Portugal, starts the comissioning of the impressive "Oman International Hospital".

2021-05-20 12:00 1757

Idealmed GHS, part of European health group IGHS, commissions new Oman International Hospital in Muscat, Oman

Kintor Announced (1) FDA Has Greenlighted Proxalutamide's Phase III Study for Hospitalized Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide's Phase III Study for Mild to Moderate COVID-19

SUZHOU, China, May 19, 2021 /PRNewswire/ -- On May 18, Kintor Pharmaceutical Limited (HKEX.9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the U.S. Food and Drug Administration (FDA) has greenlighted proxalutamide's ph...

2021-05-20 09:47 8598

Alphamab Oncology to Present Multiple Clinical Research Data at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021)

SUZHOU, China, May 20, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, data from three clinical studies of the PD-L1/CTLA-4 bispecific antibody KN046 will be presented in Poster session at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021) to be held...

2021-05-20 09:34 8573

ASCO 2021 | Ascentage Pharma to Announce Updated Data of Lisaftoclax (APG-2575) Demonstrating an ORR of Around 80% and Therapeutic Potential in Patients with R/R CLL/SLL in Oral Presentation

SUZHOU, China and ROCKVILLE, Md., May 20, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that an abstract reporting on...

2021-05-20 08:44 4330

ASCO 2021 | Ascentage Pharma to Announce Updated Results Demonstrating Clinical Potential of Alrizomadlin (APG-115) Plus Pembrolizumab in Patients with Advanced Solid Tumors that Had Failed Immunotherapies in Oral Presentation

SUZHOU, China and ROCKVILLE, Md., May 20, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts reporting on t...

2021-05-20 08:17 4605

Duality Biologics Completed $90 Million Series B Financing

PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ -- Duality Biologics (DualityBio or Company), an innovative biotech company, announced the completion of$90 million series B financing today. This round of financing was led by Lilly Asia Ventures (LAV) and jointly invested...

2021-05-20 08:00 1443

Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies

SUZHOU, China, May 20, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) d...

2021-05-20 08:00 1923

World Brain Day 2021 Dedicated to Multiple Sclerosis

World Federation of Neurology partners with the MS International Federation to promote Multiple Sclerosis awareness on World Brain Day LONDON, May 20, 2021 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce that the theme of this year's World Brain Day is Stop Multipl...

2021-05-20 07:00 1075

World Brain Day 2021 Dedicated to Multiple Sclerosis

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

* Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages * Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and tolerability with no dose-limiting toxicities; preliminary clinical activity of uliledlimab has...

2021-05-20 06:00 8171

Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

SUZHOU, China and PALO ALTO, Calif., May 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated ...

2021-05-20 05:15 8358